Gemcitabine-oxaliplatin combination (GEM-OHP) in metastatic non-small cell lung cancer (NSCLC): Final results of a phase II study

Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): A multicenter phase II study

“…The observed low incidence of severe toxicity is also in keeping to that observed in recent reports using the same drug combination in patients with advanced/metastatic NSCLC [18,19,[29][30][31][32]. In all these trials, the combination showed a low incidence of severe toxicity, indicating that the GEMOX combination is well tolerated in both untreated and pretreated NSCLC patients [18,19,[29][30][31][32].…”

“…Lippe et al [19] reported a 15.8% ORR for the combination in chemo-naïve patients, which was considered modest and the study was prematurely closed as it did not reach the statistical hypothesis. In another phase II multicenter randomized trial in chemo-naïve patients with NSCLC the objective response rate was 26% while GEMOX was associated with a favorable toxicity profile [31].…”

“…Cumulative peripheral neuropathy, consisting of cold-enhanced paresthesia, although reversible in the majority of patients remains the main toxicity associated with oxaliplatin-based chemotherapy regimens [17]. The GEMOX (gemcitabine + oxaliplatin) regimen has been evaluated very recently in NSCLC and showed considerable activity with no overlapping toxicity [18,19]. In vitro studies have shown that, the GEMOX regimen, may be synergistic with a sequence-dependency that favors the administration of gemcitabine followed by oxaliplatin [20,21].…”

Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC)

“…The ORR was 37% for oxaliplatin and vinorelbine; OS was not reported [9]. The ORR ranged from 16% to 39% for oxaliplatin and gemcitabine in five phase II studies [11][12][13]29,30], but OS was only 6 or 7 months and Lippe et al [30] concluded that the combination was not active.…”